174 related articles for article (PubMed ID: 30806949)
1. Discovery of novel inhibitors of human galactokinase by virtual screening.
Hu X; Zhang YQ; Lee OW; Liu L; Tang M; Lai K; Boxer MB; Hall MD; Shen M
J Comput Aided Mol Des; 2019 Apr; 33(4):405-417. PubMed ID: 30806949
[TBL] [Abstract][Full Text] [Related]
2. Structure-Based Optimization of Small Molecule Human Galactokinase Inhibitors.
Liu L; Tang M; Pragani R; Whitby FG; Zhang YQ; Balakrishnan B; Fang Y; Karavadhi S; Tao D; LeClair CA; Hall MD; Marugan JJ; Boxer M; Shen M; Hill CP; Lai K; Patnaik S
J Med Chem; 2021 Sep; 64(18):13551-13571. PubMed ID: 34491744
[TBL] [Abstract][Full Text] [Related]
3. Innovative therapy for Classic Galactosemia - tale of two HTS.
Tang M; Odejinmi SI; Vankayalapati H; Wierenga KJ; Lai K
Mol Genet Metab; 2012 Jan; 105(1):44-55. PubMed ID: 22018723
[TBL] [Abstract][Full Text] [Related]
4. Structure activity relationships of human galactokinase inhibitors.
Liu L; Tang M; Walsh MJ; Brimacombe KR; Pragani R; Tanega C; Rohde JM; Baker HL; Fernandez E; Blackman B; Bougie JM; Leister WH; Auld DS; Shen M; Lai K; Boxer MB
Bioorg Med Chem Lett; 2015 Feb; 25(3):721-7. PubMed ID: 25553891
[TBL] [Abstract][Full Text] [Related]
5. Fragment Screening Reveals Starting Points for Rational Design of Galactokinase 1 Inhibitors to Treat Classic Galactosemia.
Mackinnon SR; Krojer T; Foster WR; Diaz-Saez L; Tang M; Huber KVM; von Delft F; Lai K; Brennan PE; Arruda Bezerra G; Yue WW
ACS Chem Biol; 2021 Apr; 16(4):586-595. PubMed ID: 33724769
[TBL] [Abstract][Full Text] [Related]
6. High-throughput screening for human galactokinase inhibitors.
Wierenga KJ; Lai K; Buchwald P; Tang M
J Biomol Screen; 2008 Jun; 13(5):415-23. PubMed ID: 18490662
[TBL] [Abstract][Full Text] [Related]
7. Molecular and biochemical characterization of human galactokinase and its small molecule inhibitors.
Tang M; Wierenga K; Elsas LJ; Lai K
Chem Biol Interact; 2010 Dec; 188(3):376-85. PubMed ID: 20696150
[TBL] [Abstract][Full Text] [Related]
8. Structural analysis of missense mutations in galactokinase 1 (GALK1) leading to galactosemia type-2.
P S; Ebrahimi EA; Ghazala SA; D TK; R S; Priya Doss C G; Zayed H
J Cell Biochem; 2018 Sep; 119(9):7585-7598. PubMed ID: 29893426
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the enzymatic activities of human galactokinase GALK1 and a related human galactokinase protein GK2.
Ai Y; Basu M; Bergsma DJ; Stambolian D
Biochem Biophys Res Commun; 1995 Jul; 212(2):687-91. PubMed ID: 7542884
[TBL] [Abstract][Full Text] [Related]
10. The molecular basis of galactosemia - Past, present and future.
Timson DJ
Gene; 2016 Sep; 589(2):133-41. PubMed ID: 26143117
[TBL] [Abstract][Full Text] [Related]
11. Identification of Novel PI3Kδ Selective Inhibitors by SVM-Based Multistage Virtual Screening and Molecular Dynamics Simulations.
Liang JW; Wang S; Wang MY; Li SL; Li WQ; Meng FH
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31795217
[TBL] [Abstract][Full Text] [Related]
12. Discovery and Design of Novel Small Molecule GSK-3 Inhibitors Targeting the Substrate Binding Site.
Rippin I; Khazanov N; Shirley Ben Joseph ; Kudinov T; Berent E; Arciniegas Ruiz SM; Marciano D; Levy L; Gruzman A; Senderowitz H; Eldar-Finkelman H
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33218072
[TBL] [Abstract][Full Text] [Related]
13. Discovery of tyrosine kinase inhibitors by docking into an inactive kinase conformation generated by molecular dynamics.
Zhao H; Huang D; Caflisch A
ChemMedChem; 2012 Nov; 7(11):1983-90. PubMed ID: 22976951
[TBL] [Abstract][Full Text] [Related]
14. Discovery of diverse small molecule chemotypes with cell-based PKD1 inhibitory activity.
Sharlow ER; Mustata Wilson G; Close D; Leimgruber S; Tandon M; Reed RB; Shun TY; Wang QJ; Wipf P; Lazo JS
PLoS One; 2011; 6(10):e25134. PubMed ID: 21998636
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor (EGFR) structure-based bioactive pharmacophore models for identifying next-generation inhibitors against clinically relevant EGFR mutations.
Panicker PS; Melge AR; Biswas L; Keechilat P; Mohan CG
Chem Biol Drug Des; 2017 Oct; 90(4):629-636. PubMed ID: 28303669
[TBL] [Abstract][Full Text] [Related]
16. Ligand efficiency based approach for efficient virtual screening of compound libraries.
Ke YY; Coumar MS; Shiao HY; Wang WC; Chen CW; Song JS; Chen CH; Lin WH; Wu SH; Hsu JT; Chang CM; Hsieh HP
Eur J Med Chem; 2014 Aug; 83():226-35. PubMed ID: 24960626
[TBL] [Abstract][Full Text] [Related]
17. Identification of novel PI3Kδ inhibitors by docking, ADMET prediction and molecular dynamics simulations.
Liu YY; Feng XY; Jia WQ; Jing Z; Xu WR; Cheng XC
Comput Biol Chem; 2019 Feb; 78():190-204. PubMed ID: 30557817
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of human UDP-glucose pyrophosphorylase rescues galactose-1-phosphate uridyltransferase-deficient yeast.
Lai K; Elsas LJ
Biochem Biophys Res Commun; 2000 May; 271(2):392-400. PubMed ID: 10799308
[TBL] [Abstract][Full Text] [Related]
19. Functional studies of rat galactokinase.
Chu X; Li N; Liu X; Li D
J Biotechnol; 2009 May; 141(3-4):142-6. PubMed ID: 19433218
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
